A METHOD FOR PROGNOSIS OF OVARIAN CANCER, PATIENT'S STRATIFICATION
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Aug 11, 2015
filing date -
Aug 11, 2014
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
There are no reliable clinical bio-markers of survival prognosis, patient's risk stratification and treatment prediction for epithelial ovarian cancers(EOC). The most common type of the human EOC is a high grade serous EOC. This cancer is characterized with one of the lowest survival rates compared to other cancers. The present invention relates to an method for a prognosis of survival of a subject diagnosed with EOC, the method comprising determining in a sample of the subject gene expression level of at least one gene in the list of Evi1 pathway genes; and/or copy number of at least one gene in the MECOM locus; wherein the level against at least one expression threshold value will define the risk group of the subject and/or a risk of the disease progression after surgery treatment, and/or an effectiveness of post-surgery chemotherapy. The quantification method of Evi1/MECOM locus regulatory pathway provides a set of multigene prognostic signatures representing EVI1 pathway modules, which collectively provided a framwork of high-confidence, sensitive and specific prognosis assay(s) of EOC and stratification method for the EOC patient stratification according to disease relapse.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully